Overview

A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease

Status:
RECRUITING

Trial end date:
2029-12-01

Target enrollment:

Participant gender:

Summary

This study will be conducted to determine the preliminary efficacy of axatilimab in combination with ruxolitinib and to assess the contribution of axatilimab to the combination treatment effect in participants with cGVHD.

Phase:

PHASE2

Details

Lead Sponsor:

Incyte Corporation

Treatments:

Adrenal Cortex Hormones
axatilimab
Methylprednisolone
Prednisolone
Prednisone
ruxolitinib